Patrick Daly

DocwireNews

Following reports of varied responses to eltrombopag olamine in patients with immune thrombocytopenia (ITP) from different ethnic groups, researchers led by Mohamed A. Yassin assessed eltrombopag in ethnically Asian and Arab patients. Their article, published in Cureus, found that smaller dosages of eltrombopag were successful in maintaining acceptable platelet levels among these patient populations.The authors suggested that this finding could help patients derive the most benefit and the lowest viable dose, &ldquo;reducing toxicity and expense.&rdquo; They also noted that eltrombopag was generally well-tolerated and effective at achieving desired platelet outcomes in adult patients with chronic ITP.The researchers retrospectively reviewed electronic health records of non-Arab Asian (n = 17) and Arab (n = 41) patients from a single institution in Qatar. Patients were aged &ge;18 years with confirmed diagnoses of chronic ITP and were under active treatment with a platelet count of 30,000/L and bleeding symptoms. Responses to eltrombopag were reviewed after 3 or more months of therapy at dosages ranging from a minimum of 12.5 mg to a maximum dose of the typical 50 mg.According to the authors, the rate of successful response&mdash;defined as a platelet count of 50,000/L&mdash;was equivalent between non-Arab and Arab patients at 88.2% and 87.5%, respectively. However, they determined that 26% of Arab patients successfully responded to a lower dose of 12.5 mg or 25 mg, while 41.5% required the full 50 mg dose.Although the authors noted that their exploratory findings require confirmation in larger-scale studies, they advanced that a &ldquo;lowest feasible dose&rdquo; of eltrombopag is capable of providing the greatest benefit to patients, which may help reduce the incidence of adverse effects. They also suggested that &ldquo;treatment recommendations that are customized to ethnic variations can help individuals and the healthcare system save money.&rdquo;

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Latest News

Eltrombopag Responses in Arab Patients With Immune Thrombocytopenia

Following reports of varied responses to eltrombopag olamine in patients with immune thrombocytopenia (ITP) from different ethnic groups, researchers led by Mohamed A. Yassin ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe